De novo Graves’ thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease

It is well known that radioactive iodine treatment (RAI) for thyrotoxicosis in Graves' disease can precipitate worsening of thyroid eye disease (TED), particularly in susceptible patients. Less commonly, it has been associated with <i>de novo</i> development of TED in those with Graves' disease without a history. Prophylactic steroid treatment has been shown to reduce the incidence of this phenomenon in those with risk factors.Here, we describe a patient with thyrotoxicosis due to nodular thyroid disease rather than Graves' disease and normal baseline thyroid-stimulating hormone receptor antibody (TRAb) levels and no other risk factors for TED, who subsequently developed new onset TED associated with thyrotoxicosis and elevated TRAb levels following RAI.

Authors

Institutions

Publication Details

Journal
BMJ Case Reports
Published
2025-02-01
DOI
https://doi.org/10.1136/bcr-2024-263986
Citations
1
Primary Topic
Ophthalmology and Eye Disorders
Type
article
Field-Weighted Citation Impact
1.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

De novo Graves’ thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease

Adhithya Sankar, Sushmita Pearce, R. P. Singh
1 citations
BMJ Case Reports
Ophthalmology and Eye Disorders
1.47
article

De novo Graves’ thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease

Adhithya Sankar, Sushmita Pearce, R. P. Singh
article en
1 citations

Abstract

It is well known that radioactive iodine treatment (RAI) for thyrotoxicosis in Graves' disease can precipitate worsening of thyroid eye disease (TED), particularly in susceptible patients. Less commonly, it has been associated with <i>de novo</i> development of TED in those with Graves' disease without a history. Prophylactic steroid treatment has been shown to reduce the incidence of this phenomenon in those with risk factors.Here, we describe a patient with thyrotoxicosis due to nodular thyroid disease rather than Graves' disease and normal baseline thyroid-stimulating hormone receptor antibody (TRAb) levels and no other risk factors for TED, who subsequently developed new onset TED associated with thyrotoxicosis and elevated TRAb levels following RAI.

BMJ Case ReportsVol. 18(2)
Manchester University NHS Foundation Trust (GB), Royal Albert Edward Infirmary (GB)
Good health and well-being
Openalex Percentile: Top 23%
Ophthalmology and Eye Disorders
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

De novo Graves’ thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease — Adhithya Sankar, Sushmita Pearce, et al. · BMJ Case Reports (2025) | TGRS Research Map | TGRS